The document discusses the value of innovation in Canada's healthcare system. It notes that innovative medicines make up a small portion of overall healthcare spending but have contributed greatly to increased life expectancy and quality of life. However, there are myths that medicines are solely responsible for rising costs and that companies can charge whatever they want. In reality, Canada has robust systems to assess pricing and value. The document argues that both access to current treatments and support for developing new innovations must be balanced to have a sustainable healthcare system that improves outcomes for patients.

1. The Value of
Innovation in Canada
Carole Watson, Director, Strategic Pricing, Janssen Inc.
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.

2. Chris Halyk
President, Janssen Inc.
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
Artwork by Sebastian Ferreira
Janssen is proud to feature artwork created by people affected
by the illnesses and diseases we are committed to treating and preventing.

3. Dr. Paul Janssen
“There are still many diseases
for which there is no cure, and
effective medicines must be
found.
Although we have contributed to
the solutions for some of these
problems, we will continue our
research efforts, because so
much more needs to be done.”
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

4. Some Believe…
“Our healthcare system is not
sustainable because of the
cost of drugs.”
4
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

5. Medicines are responsible for the
increased costs of healthcare
Myth:
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

6. Innovative medicines make up just over 6% of
healthcare spending in Canada
Source: Canadian Health Policy Institute, Spending on Patented Drugs in Canada 1990-2014, February 23, 2016
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

7. In 15 years drug costs grew 0.5%, while all other
healthcare spending grew 13%
$0
$500
$1,000
$1,500
$2,000
$2,500
$3,000
Health Spending per capita
in Canada (Public & Private)
Hospitals, Institutions,
Capital
Physicians, Professionals
Public Health,
Administration, Health
Research, Other
Patented Drugs
Source: Canadian Health Policy Institute, Spending on Patented Drugs in Canada , 1990-2014, February 23, 2016;
7
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

8. 8
Pharmaceutical companies are
free to charge whatever they want
Myth:
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

9. Canada has robust systems for assessing price
and reimbursement
Health Canada
Patented Medicine Prices
Review Board
HTA (CDR, INESSS,
pCODR)
Pan Canadian Pharmaceutical
Alliance (pCPA)
Private Insurer
Assessments
Provincial Payer Listings
(PLAs)
“Drugwatch” type
programs
Price and value
hurdles between
innovation and
patients in Canada
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

10. § Patients are always at the center
§ Broad understanding of value –
to patients, healthcare system, society
§ Access for patients today
§ Incentive for investment in
biomedical innovation to transform the
lives of patients tomorrow
Medicines are priced to ensure patient access
today – and tomorrow
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

11. Developing innovative medicines is a long,
expensive, and risky process
Source: DiMasi et al 2016. Innovation in the pharmaceutical industry:
New estimates of R&D costs. J Health Econ. 47: 20-33.
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

12. Innovative medicines are simply
a cost to the healthcare system
and do not provide substantial
value
Myth:
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

13. Medicines help Canadians have longer,
healthier, more productive lives
73% of the
improvement in life
expectancy is estimated
to be due to medicines
over this decade
2 of 3 people diagnosed
with cancer today survive
5 years, compared to 1 in 3
in 1964
A 20-year-old diagnosed
with HIV today can expect
to live into his or her 70’s
Life expectancy: Lichtenberg, F. R., 2014. Health Policy and Technology 3, pp. 36-58. Cancer: National Cancer Institute website. Available at:
http://seer.cancer.gov/csr/1975_2012/browse_csr.php HIV: Samji, H. et al., 2012. PLOS ONE, 8(12), p. e81355.
13
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

14. Hepatitis C is curable
Medicines help Canadians have longer, healthier,
more productive lives and decrease healthcare
spending
Sources: PhRMA, 2014. http://www.phrma.org/sites/default/files/pdf/Hep-C-Report-2014-Stepping-Stones.pdf
Lichtenberg FR. Benefits and costs of newer drugs: An Update. National Bureau of Economic Research (NBER), Working Paper no. 8996, 2002.
http://www.myelomabeacon.com/news/2013/11/01/multiple-myeloma-survival-significantly-increases-last-decade/
http://www.myelomacanada.ca/docs/recent%20increase%20in%20survival%20110207.pdf
For every $1 spent on
innovative medicines, non-
medicine spending drops by $7
14
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
Patients treated for the
blood cancer Multiple
Myeloma have shown a 32%
increase in Survival – from
2000 to 2010.
16-11-09

15. Threats to the Value of Medicines within our
Healthcare System
Cost-Containment Focus
Ignoring the Value of Innovative Medicines
Therapeutic Substitution
Non-Medical Switching
Restricted Patient and HCP Choice
15
leading to…
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

16. Focus on cost-containment
16
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
PMPRB
reform
|
pCPA
|
Na1onal
Pharmacare
|Private
payers
|
SEB
first
principles
How to balance today’s budgets with
support for future innovation?
16-11-09

17. Federal Innovation Agenda
• Federal Ministry of Innovation, Science and Economic Development (ISED)
has defined a new vision to build Canada as a centre of global innovation
• $800 million in funding starting in 2017-18
• Three areas vital to Canadian innovation:
1. Clean tech
2. Life Sciences
3. IT
Life Sciences Question:
Are provincial Ministries of
Health aligned with ensuring
timely access and health system
adoption of innovative
technologies to improve health
outcomes for Canadians?
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

18. So What Do We Need To Do?
u Focus on our shared priorities
u Ensure short-term decisions do not have long-
term negative impacts
u Collaboration is key – a partnership for better
patient outcomes and healthcare sustainability
u We encourage everyone to be informed on the
value of innovation and make your voices heard
18
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.
16-11-09

19. The Value of Medicines
in Canada
Carole Watson, Director, Strategic Pricing, Janssen Inc.
Canadian Expert Patients in Health Technology Conference
Canadian Organization for Rare Disorders
November 7-8, Toronto.